Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to find out if bone marrow treatment (bone marrow aspiration and infusion of stem cells) can be safely used in adults who have recently (within 24-72 hours)suffered an acute ischemic stroke.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Autologous Cell Therapy After Stroke

NCT00908856

Stroke

WITHDRAWN PHASE1

Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke Patients

NCT01028794

Cerebral Embolism Stroke

COMPLETED PHASE1/PHASE2

Intravenous Autologous Bone Marrow-derived Stem Cells Therapy for Patients With Acute Ischemic Stroke

NCT01501773

Acute Stroke

COMPLETED PHASE2

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke

NCT01297413

Ischemic Stroke

COMPLETED PHASE1/PHASE2

Autologous Bone Marrow Stem Cells in Ischemic Stroke.

NCT00535197

Stroke, Acute Infarction, Middle Cerebral Artery

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Our primary hypothesis is that autologous bone marrow mononuclear cell transplantation by intravenous administration is feasible and safe after acute ischemic stroke. Our secondary hypothesis is that autologous transplantation is associated with improved outcome after acute stroke.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Autologous Bone Marrow Mononuclear Cells

Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.

Group Type EXPERIMENTAL

Autologous Bone Marrow Mononuclear Cells

Intervention Type BIOLOGICAL

Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autologous Bone Marrow Mononuclear Cells

Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. acute ischemic stroke
2. age 18 to 83 years If \>80 then the pre-stroke mRS needs to be \< 1)
3. Right hemisphere NIHSS 6 -15, left hemisphere NIHSS 6-18
4. known onset time of acute symptoms
5. stem cell transplantation procedure must be performed within 24 to 72 hrs after stroke symptom onset
6. TPA infusion is allowed

Exclusion Criteria

1. NIHSS 1a \> 1
2. pre-stroke mRS \> 1 if \> 80 years of age
3. Ischemic stroke in the last 3 months, any vascular territory
4. MI, primary hemorrhagic or traumatic lesion of the brain within the last 3 months or identified on MRI. Small hemorrhagic transformation of the acute infarct is allowed.
5. seizure disorder
6. developmental delay
7. chronic kidney disease defined as baseline creatinine \>1.4
8. hepatic disease or altered liver function as defined by SGPT \>150 U/L and or T. Bilirubin \>1.6 mg/dL at admission
9. pulmonary disease (e.g, COPD with oxygen-requirement at rest or with ambulation, moderate to severe asthma)
10. mechanical heart valve
11. Active malignancy or diagnosis of malignancy within 5 years prior to the start of screening or any history of chemotherapy or radiation affecting the bone marrow. Skin cancers (except for melanoma) are permitted.
12. prior immunosuppression, including chemotherapy administration within last 3 years or current immunosuppression as defined by WBC \<3 x 103 cells/ml
13. known HIV
14. hemoglobin \<10g/dl
15. uncorrected coagulopathy at the time of consent defined as INR \>1.4; PTT\>37 sec, or thrombocytopenia (PLT\<100,000)
16. any hemodynamic instability at the time of consent (e.g, requiring continuous fluid resuscitation or ionotropic support).
17. Hypoxemia (SaO2\<90%) at the time of consent, respiratory distress or persistent hypoxemia defined as SaO2 \<94% for \>30 minutes occurring at any time from hospital admission to time of consent. Intubation alone is not an exclusion.
18. pregnancy or positive b-HCG
19. current participation in any interventional research study
20. unable to return for follow-up visits for clinical evaluation, laboratory studies, or imaging evaluation
21. Multiple anti-platelet medications (Aggrenox is considered a single platelet agent)
22. Unable to undergo MRI or CT scan
23. Any other condition that the investigator feels would pose a significant hazard to the patient if enrolled.
24. Exclude infarct lesion size \>145cc unless the NIHSS 1a remains \< 1 and there is no evidence of infarct expansion or edema formation on any imaging obtained from admission up to the point just prior to infusion.
25. Exclude IA therapy use or if there is a planned or anticipated hemicraniectomy. Diagnostic angiograms are allowed

* hemispheric strokes \< 1.5 cm maximum diameter (on the MRI as seen on the diffusion-weighted imaging or CT)
* midline shift \>1mm or significant hemorrhagic transformation of the acute infarct

Minimum Eligible Age

18 Years

Maximum Eligible Age

83 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No